Which medication is classified as a leukotriene inhibitor for treating asthma?

Montelukast is classified as a leukotriene receptor antagonist, which helps in the management of asthma by inhibiting the action of leukotrienes. Leukotrienes are inflammatory mediators produced by the immune system that can cause bronchoconstriction, increased mucus secretion, and airway edema. By blocking the receptors for these leukotrienes, Montelukast reduces inflammation and bronchoconstriction in the airways, thereby improving asthma symptoms and decreasing the frequency of asthma attacks.

In contrast, Albuterol and Levalbuterol are bronchodilators that act primarily as beta-2 adrenergic agonists. They relieve acute bronchospasm but do not directly interact with leukotriene pathways. Cromolyn is a mast cell stabilizer that prevents the release of inflammatory mediators but does not specifically inhibit leukotrienes. Therefore, Montelukast is the only medication in this list that directly targets the leukotriene pathway, making it the correct choice for this question about leukotriene inhibitors in asthma treatment.